NR_Medtronic_0511_Digital.pdf

If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4

*{font-family:Arial, Helvetica, sans-serif;font-size:12px;color:#5F6265}body{background-color:#FFF;margin:0;padding:15px}h1{font-size:17px;font-weight:700;border-bottom:1px solid #D1E7B2;font-family:Tahoma, Geneva, sans-serif}li{margin-bottom:10px}a:link,a:visited,a:active,a:hover{text-decoration:underline;color:#5F6265}#application,#applicationContainer{display:none} You need a JavaScript enabled browser to view this PublicationPlease follow these steps to view the Publication:

Enable JavaScript in your browser

Refresh this page

Best regards
Zmags

S U P P L E M E N T T O M AY 2 0 1 1 Support for this supplement was provided by Medtronic, Inc. Intrathecal Baclofen Therapy: Determining Appropriate Utilization in Patients With Severe Spasticity Related to Multiple Sclerosis Mark Gudesblatt, MD, and Stephen F. Koelbel, MD Introduction Spasticity—a condition characterized by muscle stiff- ness, tightening, or spasm with associated involuntary jerking, pain, and weakness1—may be associated with stroke, spinal cord inj<a title="NR_Medtronic_0511_Digital.pdf page 1" href="http://viewer.zmags.com/publication/d436ee6e?page=1">S U P P L E M E N T T O </a> S U P P L E M E N T T O <a title="NR_Medtronic_0511_Digital.pdf page 2" href="http://viewer.zmags.com/publication/d436ee6e?page=2">Intrathecal Baclofen Therapy: Determining Appropr</a> Intrathecal Baclofen Therapy: Determining Appropr<a title="NR_Medtronic_0511_Digital.pdf page 3" href="http://viewer.zmags.com/publication/d436ee6e?page=3">sponse patterns, and possible functional out</a> sponse patterns, and possible functional out<a title="NR_Medtronic_0511_Digital.pdf page 4" href="http://viewer.zmags.com/publication/d436ee6e?page=4">ratory depression, hypotension, temporary weaknes</a> ratory depression, hypotension, temporary weaknes<a title="NR_Medtronic_0511_Digital.pdf page 5" href="http://viewer.zmags.com/publication/d436ee6e?page=5">reported good or very good levels of overall sati</a> reported good or very good levels of overall sati<a title="NR_Medtronic_0511_Digital.pdf page 6" href="http://viewer.zmags.com/publication/d436ee6e?page=6">Overcoming Barriers toTreatment With ITB Therapy</a> Overcoming Barriers toTreatment With ITB Therapy<a title="NR_Medtronic_0511_Digital.pdf page 7" href="http://viewer.zmags.com/publication/d436ee6e?page=7">RESOURCESPhysician FinderHow to find a special</a> RESOURCESPhysician FinderHow to find a special<a title="NR_Medtronic_0511_Digital.pdf page 8" href="http://viewer.zmags.com/publication/d436ee6e?page=8">SynchroMed® II Drug Infusion System Brief Summary</a> SynchroMed® II Drug Infusion System Brief Summary<a title="NR_Medtronic_0511_Digital.pdf page 9" href="http://viewer.zmags.com/publication/d436ee6e?page=9">LIORESAL® INTRATHECAL(baclofen injection)Abrup</a> LIORESAL® INTRATHECAL(baclofen injection)Abrup<a title="NR_Medtronic_0511_Digital.pdf page 10" href="http://viewer.zmags.com/publication/d436ee6e?page=10">catheter (especially disconnection), low volume i</a> catheter (especially disconnection), low volume i<a title="NR_Medtronic_0511_Digital.pdf page 11" href="http://viewer.zmags.com/publication/d436ee6e?page=11">INCIDENCE OF MOST FREQUENT (≥1%) ADVERSE EVENTS I</a> INCIDENCE OF MOST FREQUENT (≥1%) ADVERSE EVENTS I<a title="NR_Medtronic_0511_Digital.pdf page 12" href="http://viewer.zmags.com/publication/d436ee6e?page=12">INCIDENCE OF MOST FREQUENT (≥ 1%) ADVERSE EVENTS </a> INCIDENCE OF MOST FREQUENT (≥ 1%) ADVERSE EVENTS <a title="NR_Medtronic_0511_Digital.pdf page 13" href="http://viewer.zmags.com/publication/d436ee6e?page=13"> Maintenance dosage for long term contin</a> Maintenance dosage for long term contin